| The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation | | |
| Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case–control analyses from UK primary care | BMJ Open | 2022 |
| Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation | Drug Metabolism and Personalized Therapy | 2020 |
| Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism | Journal of Thrombosis and Thrombolysis | 2020 |
| Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism | Journal of Thrombosis and Thrombolysis | 2020 |
| Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study | British Journal of Clinical Pharmacology | 2020 |
| Drug-Drug Interactions with Direct Oral Anticoagulants | Clinical Pharmacokinetics | 2020 |
| A Review of the Medical Challenges of Using Direct Oral Anticoagulants in Real-World Practice | Therapeutic Innovation and Regulatory Science | 2020 |
| Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review | Frontiers in Medicine | 2020 |
| The myth of 'stable' coronary artery disease | Nature Reviews Cardiology | 2020 |
| Cardiovascular Risk Management and Hepatitis C: Combining Drugs | Clinical Pharmacokinetics | 2019 |
| Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK | BMJ Open | 2019 |
| Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome | Clinical Drug Investigation | 2019 |
| Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease | Circulation | 2019 |
| Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants | Journal of Thrombosis and Haemostasis | 2019 |
| Role of rivaroxaban in the prevention of atherosclerotic events | Expert Review of Clinical Pharmacology | 2019 |
| Initial rivaroxaban dosing in patients with atrial fibrillation | Clinical Cardiology | 2019 |
| How Does "Regulatory Practice" Create Discrepancies in Drug Label Information Between Asian and Western Countries? Different Label Information for Direct Oral Anticoagulants Approved in the United States, Europe, Korea, and Japan | Therapeutic Innovation and Regulatory Science | 2019 |
| Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report | Chest | 2018 |
| Oral Anticoagulation in Patients With Liver Disease | Journal of the American College of Cardiology | 2018 |
| Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation | Thrombosis Journal | 2018 |
| Global Prospective Safety Analysis of Rivaroxaban | Journal of the American College of Cardiology | 2018 |
| XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia | Journal of Arrhythmia | 2018 |
| Rivaroxaban prescribing in a Saudi tertiary care teaching hospital | Saudi Pharmaceutical Journal | 2018 |
| Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants | Medicina Clínica (English Edition) | 2018 |
| Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study | Thrombosis Journal | 2018 |
| Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice | British Journal of Clinical Pharmacology | 2018 |
| Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians | Journal of Thrombosis and Haemostasis | 2018 |
| Direct-acting oral anticoagulant drug level monitoring in clinical patient management | Journal of Thrombosis and Thrombolysis | 2018 |
| Rivaroxaban Induced Thrombocytosis: A Perplexing Clinical Challenge | Indian Journal of Hematology and Blood Transfusion | 2018 |
| Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants | Medicina Clínica | 2018 |
| Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting | Oncologist | 2018 |
| Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations | CPT: Pharmacometrics and Systems Pharmacology | 2018 |
| Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban | Current Medical Research and Opinion | 2018 |
| Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury | Journal of the American College of Cardiology | 2018 |
| Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis | British Journal of Clinical Pharmacology | 2017 |
| Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs | European Journal of Clinical Pharmacology | 2017 |
| Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation | Expert Opinion on Pharmacotherapy | 2017 |
| Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study | Journal of Thrombosis and Haemostasis | 2017 |
| Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA) | European Heart Journal - Cardiovascular Pharmacotherapy | 2017 |
| Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation | Expert Opinion on Pharmacotherapy | 2017 |
| Medication errors involving anticoagulants: Data from the Danish patient safety database | Pharmacology Research and Perspectives | 2017 |
| Perioperative management of patients on direct oral anticoagulants | Thrombosis Journal | 2017 |
| Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin | Journal of Thrombosis and Haemostasis | 2017 |
| Effect of Activated Charcoal on Rivaroxaban Complex Absorption | Clinical Pharmacokinetics | 2017 |
| Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation | Journal of Thrombosis and Thrombolysis | 2017 |
| Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report | Journal of Medical Case Reports | 2017 |
| Use of rivaroxaban in patients with stroke | Neurological Sciences | 2017 |
| Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions | British Journal of Clinical Pharmacology | 2017 |
| [From clinical trials to clinical practice. Experience with rivaroxaban in the anticoagulant treatment of patients with non-valvular atrial fibrillation] | Semergen | 2017 |
